—
strategy: Kepler Cheuvreux makes a surprising turnaround in pharmaceutical stocks and goes to OVERWEIGHT (underweight). In return, downgrades the technology sector to UNDERWEIGHT (overweight) and the semiconductor stocks to NEUTRAL (overweight). Investment rating for the Swiss equity market recently NEUTRAL (underweight).
Siegfried: Drops bomb. We got the Covid-19 vaccine from Biontech and Pfizer bottling. Hopes that this will generate additional sales in the high double-digit million range. Mirabaud Securities remains at BUY up to CHF 600. ZKB sees high potential, is for OVERWEIGHT.
AMS: JP Morgan warns of a painful slowdown in sales of previous iPhones of the US major customer Apple with a view to bringing 5G-enabled devices to market. Also affects suppliers like AMS.
Aryzta: A bang for the heavily indebted bakery manufacturer. Andreas Schmid withdraws his candidacy. Has the die already been cast?
Ascom: Shareholder group around asset manager Veraison dissolves. Possible company sales abroad are probably off the table, according to dealers.
Cosmo Pharma: Sales of titles from the carpet floor for CHF 1.7 million.
Ems-Chemie: Research Partners go to SELL (hold) up to CHF 650. Share price trend anticipates an early return of the automotive industry to the growth path.
Helvetia: Half-year loss of CHF 17 million with gross premiums of CHF 5.66 billion. Combined ratio 95.9 percent. Number wreath does not hold any major surprises. Vontobel for HOLD up to CHF 98.
Landis+Gyr: Vontobel is up to CHF 59 (67) for HOLD. Turnaround in the USA is delayed by years. Persistent margin pressure.
Lonza: Develops capacities with Humanigen for Covid-19 candidates.
Nestle: Bryan Garnier goes on CONVICTION BUY (Buy) to 125 (118) Fr. Has a higher proportion of affordable products for consumers than other rivals.
SGS: HSBC increases to HOLD (Reduce) to 2350 (1850) Fr. And again one less sales recommendation.
Derivatives: Early activities in the BIOSJB call warrant BB Biotech as well as in the Long Mini-Futures MSMAIV on the SMI.
–
